Despite the advances made in the last 40 years, the survival rates for AML are less than desirable, remaining around 70% at 5 years, even for good responders to induction therapy.(2) New therapies are already being used for gene variants of AML, such as FLT3 (midostaurin and gilterinib), BCL2 (venetoclax), and IDH1/IDH2 (ivosidenib and enasidenib) inhibitors.(3) However, such alternative therapies are not yet widely used, either because of their cost or because they require approval for use in Brazil. Here, IDH1 is linked to acute myeloid leukemia.